ASTH earnings call summary

Prepared Highlights

• Total revenue of $956M in Q3 2025, up 100% YoY and 46% sequentially, driven by Prospect Health acquisition and organic growth (CEO, CFO).
• Adjusted EBITDA of $68.5M, up 52% YoY and 42% sequentially (CEO, CFO).
• Medical cost trend stable and in line with expectations across both legacy Astrana and Prospect; legacy Astrana Medicare trended below 4.5% aggregate expectation; Medicaid trend decelerated vs Q2 (CEO).
• Prospect integration on track: synergy target of $12M–$15M reiterated; live visibility into utilization metrics; full platform onboarding expected by mid-2026 (CEO).
• Cash and short-term investments of ~$463M; net debt of ~$624M; net leverage ratio ~2.5x pro forma trailing 12-month adjusted EBITDA (CFO).
• Cash flow from operations of ~$10M in Q3; 9-month total $118M; full-year FCF conversion expected 40%–45% of adjusted EBITDA (CFO).
• New partnerships: expanded Intermountain Health in Nevada; new Care Enablement partnership with a provider group serving >40,000 members in value-based care, onboarding in H1 2026 (CEO).
• AI initiatives: predictive models for high-risk patients; LLM integrated into platform for clinician queries of longitudinal medical records (CEO).
• Official guidance (FY2025): revenue $3.1B–$3.18B; adjusted EBITDA $200M–$210M; update reflects timing shift of full-risk contracts from mid-2025 to Q1 2026, not underlying performance (CEO, CFO).
• 2026 outlook: tailwinds from improved Medicare Advantage rates, Prospect synergies, full-risk cohort maturation; headwinds from Medicaid/exchange regulatory dynamics (CEO).

Mgmt Quotes

• “Astrana delivered another strong quarter of financial and operational results… this was an especially important quarter as we welcomed new providers, patients and team members after the close of our acquisition of Prospect Health.” (CEO)
• “Medical cost trends across both Prospect and Astrana's core business remained firmly within expectations during the third quarter, underscoring the consistency and predictability of our operating model.” (CEO)
• “We have not and will not enter into full risk contracts simply to accelerate the top line. We do so only when the data, infrastructure and financial alignment are in place to manage that risk responsibly and sustainably.” (CEO)
• “Our third quarter results reflect strong execution and continued consistency across the business. We successfully integrated Prospect into our consolidated financials while maintaining solid performance across legacy Astrana operations.” (CFO)
• “We continue to expect to reduce leverage within the next 12 months through a combination of EBITDA growth and free cash flow generation.” (CFO)

Prepared Metrics

Q&A Batch (1-5 of 5)

Q1 — Jailendra Singh

• Topic: 收入指引下调源于完整风险转换时间延迟，涉及支付方及合同细节
• Key points:
  • 延迟仅为时间问题，承诺在2026年第一季度完成转换；涉及Legacy Astrana和Prospect双方业务，原因为合同标准化与整合
  • 约一半延迟是程序性（监管文件、双向数据运营反馈），预计1月1日解决；另一半处于后期谈判，预计2026年第一季度完成；涉及多个支付方
  • EBITDA下调1000万美元完全由该时间延迟造成；核心趋势（医疗成本趋势）在Legacy Astrana和Prospect均符合或略好于预期
• Mgmt stance: bullish – 对延迟解决有信心，强调双方合作互利，且核心趋势健康

Q2 — Matthew Mardula

• Topic: 医疗补助（Medicaid）成本趋势及新合作团队盈利性
• Key points:
  • 医疗补助成本趋势持续改善，但监管环境不稳定；预计2026年晚期边际可能稳定
  • Q4季节性已纳入指引，管理层有足够信心
  • 新合作团队（南加州，超4万名成员）组合类似：Medicare/Medicaid/商业混合，全部为共享风险成员，非完整风险；按收入比例收取费用
  • 预计该业务早期即对EBITDA产生正向贡献，因为Care Enablement的运营杠杆高
• Mgmt stance: neutral-to-bullish – 医疗补助仍面临逆风但趋势改善，新合作被视为EBITDA附加项

Q3 — Meghan Holtz

• Topic: 分部门利润率：Care Enablement利润率极高，Care Partners偏低
• Key points:
  • Care Enablement在Q3增长迅速，主要受益于Legacy Prospect的大型enablement业务及新客户；EBITDA利润率强劲，预计持续增长
  • Care Partners利润率较低源于Legacy Prospect业务医疗成本趋势略高（较核心业务），且存在季节性；所有因素已纳入指引
  • 未来有机会将Care Partners的MLR向Legacy Astrana水平靠拢
• Mgmt stance: bullish – 对Enablement增长和利润持续看好，Care Partner利润率是暂时性且可改善

Q4 — Michael Ha

• Topic: 医疗补助成员退出（disenrollment）趋势及2027年Medicare Advantage利率对利润率的影响
• Key points:
  • 2025年医疗补助年化中期至高位单数字退出率，低于部分州报告（如加利福尼亚）；原因为长期会员关系及计划保留高质量网络成员
  • 2026年MA利率增长不错，但未完全覆盖全国8%–10%的趋势（参考ACO REACH RTA报告）；V28无显著逆风
  • 预计2027年MA利率通知可能为中等至高位单数字，有望支撑利润率企稳并开始扩张；管理层已做内部情景规划
• Mgmt stance: neutral-to-bullish – 医疗补助退出可控，MA利率趋势对利润率有利，但A

Q&A Batch (6–10 of 10)

Q6 — Thomas Walsh

• Topic: Prospect cost trend vs. legacy Astrana
• Key points:
  • Stand-alone Prospect cost trend not disclosed; expected to be "several points higher" than legacy Astrana.
  • Management believes this is not structural; integration of contracts, clinical pathways, and technology platform offers opportunity to narrow the margin gap.
  • Prospect business performed in line with expectations during diligence and post-acquisition.
• Mgmt stance: Neutral — acknowledges higher trend but sees a clear path to margin improvement through operational integration.

Q7 — David Larsen

• Topic: Medical cost trend and exchange exposure
• Key points:
  • Blended weighted average trend was "just under 4.5%" for the legacy Astrana business, in line with expectations; Medicare trend better, Medicaid decelerated vs. Q2, commercial stable.
  • 2026 trend expectations not yet shared; management will be conservative given potential regulatory headwinds for Medicaid and exchange.
  • Exchange membership is small (~3% of revenue), considered manageable exposure.
  • Claim completion rates >85% consistently; no negative prior period development for many quarters, including on risk adjustment.
• Mgmt stance: Bullish — confident in cost trend management and data completeness, with no surprises expected.

Q8 — Craig Jones

• Topic: Reconciliation bill work requirements and V28/V29 risk adjustment
• Key points:
  • Work requirements expected to be a "2027 item" under current construction; no near-term impact.
  • Potential headwinds in 2026 from related items like UIS status members.
  • V28 has not hurt Astrana; management believes RAF is "almost too low" and is unconcerned about potential V29 changes.
• Mgmt stance: Bullish — confident in risk adjustment accuracy and ability to adapt to model changes.

Q9 — Zachary Haggerty

• Topic: Full-risk transition timing and 2026 outlook
• Key points:
  • Full-risk revenue expected to remain in the "high 70s percent" range into 2026; delayed contracts turned on in Q1 2026.
  • Several other four-risk contracts (outside of the delayed ones) are anticipated to go live in 2026 with no signs of failure.
  • Texas starting fully delegated (claims, ops, full data visibility) on 1/1/2026.
  • Delays are "one-time" and not indicative of cost trend issues in core businesses.
• Mgmt stance: Neutral — acknowledges a slight delay but reaffirms contractual movements are generally on track.

Q10 — Eugene Mannheimer

• Topic: Organic growth and new business win
• Key points:
  • Core Astrana business growing in the "mid-teens, low teens" area; Prospect growing in the "mid- to high single digits" (exclusive of full-risk movements and AEP).
  • New 40,000-lives group in Southern California is a separate client, not related to Prospect; pipeline remains strong.
  • Care Enablement business expanding with technology to support attractive pricing and growth.
• Mgmt stance: Bullish — emphasizes strong organic growth in both businesses and successful pipeline expansion.